Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a nex ...

Aptevo's Peter Pavlik, PhD, to chair a session on 'Bi and Multispecific Biologics' and will also give talk titled 'Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ ...

The 13 th Annual World Multispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover ...

Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR Plat ...

Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ...

Tessellate BIO has appointed Dr Lara Boyd as Chief Business Officer.

Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR ...

Aptevo’s Peter Pavlik, PhD, to chair a session on “Bi and Multispecific Biologics” and will also give talk titled “Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ...

The approval strengthens ABBV’s oncology portfolio and addresses critical unmet needs in advanced gynecologic cancers. On ...